EZH2 and diffuse large B-cell lymphoma: But the clinical trial outcomes of GSK126, another EZH2 inhibitor, in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), multiple myeloma (MM), and other solid tumors were unsatisfactory (19, 20).